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SPARSELY IONIZING DIAGNOSTIC AND NATURAL BACKGROUND
RADIATIONS ARE LIKELY PREVENTING CANCER AND OTHER 
GENOMIC-INSTABILITY-ASSOCIATED DISEASES 
Bobby R. Scott, Jennifer Di Palma  Lovelace Respiratory Research Institute,
2425 Ridgecrest Drive SE, Albuquerque, NM 87108
 Routine diagnostic X-rays (e.g., chest X-rays, mammograms, computed tomography
scans) and routine diagnostic nuclear medicine procedures using sparsely ionizing radia-
tion forms (e.g., beta and gamma radiations) stimulate the removal of precancerous neo-
plastically transformed and other genomically unstable cells from the body (medical radi-
ation hormesis). The indicated radiation hormesis arises because radiation doses above an
individual-specific stochastic threshold activate a system of cooperative protective process-
es that include high-fidelity DNA repair/apoptosis (presumed p53 related), an auxiliary
apoptosis process (PAM process) that is presumed p53-independent, and stimulated
immunity. These forms of induced protection are called adapted protection because they
are associated with the radiation adaptive response. Diagnostic X-ray sources, other
sources of sparsely ionizing radiation used in nuclear medicine diagnostic procedures, as
well as radioisotope-labeled immunoglobulins could be used in conjunction with apopto-
sis-sensitizing agents (e.g., the natural phenolic compound resveratrol) in curing existing
cancer via low-dose fractionated or low-dose, low-dose-rate therapy (therapeutic radiation
hormesis). Evidence is provided to support the existence of both therapeutic (curing
existing cancer) and medical (cancer prevention) radiation hormesis. Evidence is also
provided demonstrating that exposure to environmental sparsely ionizing radiations, such
as gamma rays, protect from cancer occurrence and the occurrence of other diseases via
inducing adapted protection (environmental radiation hormesis).
Keywords: radiation hormesis, adaptive response, LNT
INTRODUCTION
Ionizing radiation spans the universe in which we reside (Bonner
2003). There are two basic forms of ionizing radiation: electromagnetic
and particulate. Electromagnetic radiation is comprised of uncharged
photons (entities without mass) that interact with electrons in matter
causing ionizations if photon energy is high enough. Examples of ioniz-
ing electromagnetic radiations are X-rays and gamma rays. Examples of
particulate ionizing radiation are alpha and beta particles emitted by
radioisotopes and protons ejected from the sun. Neutrons do not direct-
ly cause ionizations but cause them indirectly through secondary charged
particles such as protons (e.g., from water in biological tissue) that are
dislodged by neutrons. 
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Natural background ionizing radiation on earth comes from the fol-
lowing three sources: the sun (solar radiation), outer space (cosmic rays),
and terrestrial sources (e.g., radionuclides in our bodies and environ-
ment, and radon in the home) (NCRP 1997). While most solar radiation
is electromagnetic, the sun also produces particulate radiation (solar cos-
mic rays), including protons, which vary with the solar cycle. 
All organisms on earth are constantly bombarded by cosmic radiation
from outside our solar system. This radiation is comprised of charged par-
ticles ranging in atomic mass from protons to iron nuclei. These particles
interact in the atmosphere creating secondary radiation that rains down
and includes X-rays, electrons, protons, alpha particles, neutrons, pions,
and muons. Our exposure to cosmic rays increases each time we take an
airline flight. Persons living at high elevations such as in Denver, Colorado,
and Salt Lake City, Utah, receive higher exposures to cosmic rays than do
persons residing in Miami, Florida, or New Orleans, Louisiana.
Natural radioactivity (the capacity to emit particulate or electromag-
netic ionizing radiation forms) is everywhere on earth. All organisms on
earth are continuously exposed to varying amounts of natural radiation.
We humans are irradiated from: radioactivity in our bodies (e.g., associ-
ated with potassium-40), natural radioactivity in ingested foods (e.g., asso-
ciated with carbon-14), exposure to radiation emanating from soils and
rocks (e.g., from uranium and thorium isotopes), and exposure in our
homes and businesses to radon and its radioactive daughter radionu-
clides. Thus, we humans are continuously exposed to radiation arising
from naturally occurring terrestrial radioactivity and from the cosmos.
This is true prior to birth and through one’s entire life. 
Diagnostic X-rays (chest X-rays and computed tomography scans) and
other sources of radiation used in nuclear medicine diagnostic procedures
are also sources for our exposure to low-level ionizing radiation. Both expo-
sure to natural background sparsely ionizing radiation and exposure to
diagnostic sparsely ionizing radiation sources are likely playing a beneficial
role in the maintenance and preservation of life on earth through sup-
pressing genomic-instability-associated diseases such as cancer. This topic is
partly the focus of this paper. An additional focus is on the use of low doses
and dose rates of sparsely ionizing radiation in curing existing cancer.
The potential for severe radiation damage is generally evaluated
based on what is called linear energy transfer (LET), which is just the
average energy loss when penetrating a small thickness of material (e.g.,
tissue). Low-LET radiations include X-rays, gamma rays, and beta parti-
cles. These radiation forms deposit relatively small amounts of energy
when penetrating a small thickness of tissue. High-LET radiation (e.g.,
alpha particles and neutrons) deposit more energy in the indicated small
thickness of tissue. High-LET radiations usually cause more biological
damage locally in tissue than low-LET radiation.
Sparsely ionizing diagnostic and natural background radiations
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It is important to be aware that small amounts of radiation kill only a
few cells and those cells are generally replaced without harm in humans
and other mammals. Radiation also produces sublethal damage to our
cells, and most such damage is repaired without any significant error
(e.g., error free). However, some cells commit repair errors (i.e., misre-
pair leading to mutations). Mutations represent a form of genomic insta-
bility. A certain amount of instability is tolerated by cells and the instabil-
ity can propagate over subsequent cellular generations. Cells with threat-
ening instability may commit suicide (apoptosis) or may be eliminated via
the immune system. Uncontrolled instability in the genome can result in
cancer and other diseases. 
The oxygen we breathe is by far the greatest natural cause of cellular
damage–many orders of magnitude greater than other natural causes
(Pollycove and Feinendegen 2003). All living mammals have a system of
protective processes that prevents, repairs, and removes cell damage.
Radiation primarily affects the components of this protective system. Low
doses activate protection resulting in fewer mutations, neoplastic trans-
formation, and cancers, while high doses suppress some of the protection
resulting in more of the indicated stochastic effects (Feinendegen et al.
2004; Scott 2005a,b, 2006a,b). 
The recently released BEIR VII Report (Phase 2) has implicated diag-
nostic X-rays (e.g., chest X-rays, mammograms, CT scans) and nuclear
medicine diagnostic procedures as causing harm through inducing
excess cancers (NRC 2006). This view is based on the linear-no-threshold
(LNT) hypothesis of radiation carcinogenesis, which states that cancer
risk increases as a LNT function of radiation dose, no matter how small.
Relative risk (RR) therefore is expected to increase linearly without a
threshold from a value of 1 at natural background radiation exposure
(usually assigned a dose of zero). RR is just the risk after exposure to radi-
ation divided by the risk when exposed only to natural background radi-
ation. Thus, without any radiation exposure beyond the natural back-
ground level, RR would equal 1 (normal risk). With excess cancers
induced by the above natural background irradiation, RR would be
greater than 1 under the LNT assumption. However, according to the
LNT hypothesis, even natural background radiation is harming us.
Reducing background radiation exposure would be expected to reduce
risk, although this appears not to be the case as is discussed later.
Cancer risk estimates based on the LNT hypothesis (Figure 1) are
mainly based on extrapolating high-dose cancer mortality data acquired
following the nuclear blasts that took place in Hiroshima and Nagasaki,
Japan, to low doses (NRC 2006). A LNT cancer risk curve is fitted to the
high-dose cancer frequency data, as was done in the BEIR VII Report
(NRC 2006). For evaluating cancer risk after low doses and dose rates, a
low-dose and dose-rate effectiveness factor (DDREF) is then used to reduce
B. R. Scott and J. Di Palma
232
3
Scott and Di Palma: Sparsely ionizing diagnostic and natural background radiations
Published by ScholarWorks@UMass Amherst, 2014
Sparsely ionizing diagnostic and natural background radiations
233
the slope of the curve by a fixed amount (Figure 1). By using the DDREF
approach, the BEIR VII Report essentially dismissed the radiation horme-
sis phenomena since only positive slopes are permitted for the dose-
response curve. With hormesis, low doses protect against cancer and other
diseases leading to a negative initial slope for the dose-response curve.
However, high doses fail to induce protection and even inhibit protection
causing risk to then increase as dose increases further, leading to what has
been called a J-shaped (or U-shaped) hormetic dose-response curve. 
In contrast to the BEIR VII Report use of the LNT hypothesis when
assessing low-LET radiation-associated cancer risk at low doses and dose
rates, the recent French Academies report related to LNT dismissed the
LNT hypothesis for low-LET radiation doses less than 100 mGy and found
radiation hormesis to be plausible (Tubiana 2005; Tubiana et al. 2005).
This paper presents evidence that we are unlikely to be harmed by
infrequent applications of diagnostic X-rays (from a chest X-ray machine,
mammogram, or CT scan), by most routine nuclear medicine procedures
or by elevated natural background radiation (including radon in our
homes). More importantly, this paper provides evidence that low levels of
low-LET radiation (e.g., X-rays or gamma rays) received from natural and
medical sources protect us from cancer and other diseases via stimulating
a system of known protective processes. Similar protection also appears to
be associated with combined exposure to low doses and dose rates of
alpha plus gamma radiation (as occurs for radon in the home). 
FIGURE 1. LNT risk function which is usually based on data derived from high doses delivered at
high rates from the atomic bombings in Hiroshima and Nagasaki, Japan. The high-dose LNT curve
is reduced by a DDREF when evaluating the risks at low doses and dose rates. Even so, the slope of
the dose-response curve can never be negative (i.e., a hormetic response curve). The notation 0+ is
used to represent the natural background radiation dose, presented as though it were located at zero.
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LOW-DOSE/DOSE-RATE LOW-LET RADIATION-INDUCED 
SYSTEM OF PROTECTION
As previously indicated, low doses and dose rates of low-LET radiation
activate a system of cooperative protective processes in the body. The pro-
tective processes include (1) defenses such as scavenging of reactive oxy-
gen species and other toxins, (2) presumably p53 related activated high-
fidelity DNA repair/apoptosis, (3) a novel auxiliary protective apoptosis
mediated (PAM) process that selectively eliminates aberrant cells, and (4)
induced immunity (Liu et al. 1994; Liu, 2004). The PAM process has been
demonstrated to involve reactive oxygen and nitrogen chemical species,
specific cytokines (e.g., transforming growth factor beta in the case of
fibroblast cells), and can occur independently of the p53 gene (Scott
2004, 2005a; Scott et al. 2006). The indicated protective processes, which
are activated by low doses and dose rates of low-LET radiation or low plus
high-LET radiation appear to be inhibited by moderate and high doses (a
characteristic of hormetic effects). The PAM process appears not to be
activated by high-LET alpha radiation alone (Scott 2004, 2005a, 2006a).
However, more research is needed to confirm this. 
In this article the idea is put forth that low doses and dose rates of
diagnostic X-rays, gamma rays, and beta radiation can prevent cancer
occurrence via stimulating selective removal of precancerous neoplasti-
cally transformed cells that could otherwise lead to cancer. In the next
section, we briefly discuss publications which indicate that low doses of
low-LET radiation are protecting us from mutations, neoplastic transfor-
mation, and cancer (including cancer metastasis) and other diseases.
EVIDENCE THAT LOW-DOSE RADIATION PROTECTS US
Low doses of low-LET radiation (gamma or X-rays) have been demon-
strated to
• Induce defense such as detoxification of reactive oxygen species (for re-
view, see Feinendegen et al. 2004).
• Induce high-fidelity repair of DNA damage (Joiner et al. 1999;
Rothkamm and Löbrich 2003).
• Protect from chromosomal damage from a subsequent high radiation
dose (Wolff et al. 1988).
• Protect from spontaneous mutations occurrence in vivo (Hooker et al.,
2004; Scott et al. 2006) . 
• Protect from spontaneous neoplastic transformation occurrence in
vitro (Azzam et al. 1996; Redpath et al. 2001; Redpath et al. 2003;
Redpath 2005; Ko et al. 2004; Elmore et al. 2005).
• Protect from spontaneous cancers in animals (Sakai 2003).
B. R. Scott and J. Di Palma
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• Extend tumor latency in cancer-prone mice (Mitchel et al. 2003;
Mitchel 2004, 2005)
• Activate the immune response (Liu et al. 1987; Makinodan and James
1990; Sakamoto et al. 1997; Liu 2003, 2004) and suppress lung and
lymph node metastasis in vivo (Hosoi and Sakamoto 1993; Hashimoto
et al. 1999; Sakamoto 2004).
• Suppress spontaneous cancers in humans (Howe, 1995; Rossi and
Zaider 1997; Scott 2005a, 2006a).
• Protect from some diseases other than cancer (Luckey 1991; Wang et al.
2005).
The low-LET radiation doses that protect us fall into a presently not-
well-defined dose zone which is dose-rate and exposure-duration depend-
ent (Scott 2004, 2005a; Scott et al. 2006). For brief exposure at a high rate
to X-rays (28-kVp, 60-kVp, or 250-kVp) and for neoplastic transformation
the protective zone includes doses in the 0.5 mGy to 10 mGy range (Scott
2004, 2005a). The 28-kVp X-rays are representative of mammographic-
energy X-rays (Ko et al. 2004). For high-energy, gamma-ray photons, the
protective zone includes doses in the range 1 mGy to 100 mGy. For pro-
tracted exposure of humans, the zone is increased to include total doses
over several hundred miligray as discussed later, related to multiple appli-
cations of fluoroscopy and mammography.
Doses currently associated with applications of X-rays and other rou-
tine diagnostic radiations fall in the protective zone (Tables 1 and 2) and
therefore are likely protecting us from cancer and some other diseases.
Unfortunately, because of the BEIR VII Report (NRC 2006) claim that
any amount of radiation is harmful, many citizens are now terrified of
having to undergo diagnostic chest X-rays, mammograms, CT scans, or
nuclear medicine diagnostics. Using a LNT risk function, the BEIR VII
Report (NRC 2006) concluded that such diagnostic treatments harm us
through inducing cancers. To the contrary, research results presented in
this paper and elsewhere (Scott 2005a, 2006a) suggest that some precan-
cerous neoplastically transformed cells in the body disappear (medical
radiation hormesis) as a result of the low-level, low-LET radiation expo-
TABLE 1. Doses from routine diagnostic X rays and possibility of hormesis induction
Number of X rays Dose rangea Hormesis likely?
< 5 0.01 mGy – 30 mGy > 0.01 mGy Yes*
5 – 14 0.1 mGy – 50 mGy Yes*
≥ 14 1 mGy – 230 mGy Yes*
*Scott (2005a); Scott et al. (2006) 
aBoice et al. (1991)
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sure associated with diagnostic X-rays. Multiple X-rays (e.g., from CT
scans, mammograms, chest X-rays) at appropriate intervals (not yet deter-
mined) would be expected to increase the efficiency of removal of the
neoplastically transformed cells as well as other genomically unstable
cells. Repeated low doses of X-rays likely over and over stimulate the tran-
sient PAM process and immunity. The indicated low-dose-radiation-
induced system of protection is illustrated in Figure 2. The protection fac-
tor (PROFAC) in Figure 2 is discussed later. Once activated, the indicated
system of protection could eliminate existing precancerous cells in the
body, e.g., those that arise from cigarette smoking. Activating the protec-
TABLE 2. Doses from typical diagnostic radiation sources in the United States and possibility for
hormesis inductiona
Source mGy Hormesis likely?
Dental, full-mouth (X ray) 0.17 Yesb
Chest X ray 0.25 Yesb
Mammograms (X ray) 4 Yesb
CT scan, head (X ray) 20 Yesb
CT scan, body (X ray) 60 Yesb
Thyroid scans:
Iodine-131 (β + γ radiation) 50-100 Yesb
Iodine-123 (γ radiation) 30-50 Yesb
Technetium-99 (β radiation) 10 Yesb
aKauffman (2003)
bScott 2005a; Scott et al. (2006)
FIGURE 2. Low-dose, low-LET-radiation-induced system of protection against spontaneous cancers.
The indicated protective components are features of the HRR model. Increasing DNA fidelity influ-
ences the slope parameter KL while the PAM process and induced immunity influence the PROFAC.
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tive system by low-dose, low-LET radiation could also protect us from
harm from other genotoxicants we are exposed to in the environment
and the workplace.
HORMESIS-BASED VS. LNT-BASED RELATIVE RISK
As already indicated, cancer RR after low doses of ionizing radiation
of any type is most often assessed based on the LNT hypothesis. However,
in the case of hormesis (a beneficial effect of irradiation, with cancer
cases decreasing below the spontaneous level), RR would be less than 1
after low radiation doses in excess of natural background radiation, when
evaluated relative to the cancer risk at background radiation exposure.
The hormetic response is presumed to be associated with the system of
radiation-induced protective processes (PAM process [presumed p53-
independent], immune system stimulation, and activated high-fidelity
DNA repair/apoptosis [presumed p53-dependent]), leading to a reduc-
tion in cancer incidence below the spontaneous incidence (Scott 2004,
2005a, 2006a,b).
Figure 3 shows the expected RR dose-response curve general shape
based on our new quantitative hormetic RR (HRR) model (Scott
2006a,b) when radiation doses range from absolute zero, 0, to above the
FIGURE 3. Basic features of the HRR model. Doses 0 and 0+ represent absolute zero radiation and
natural background radiation dose respectively. The dose D* is the dose rate and radiation quality
dependent dose at which the hormetic effect is maximal. Individual specific thresholds for activating
the system of protective processes associated with radiation hormesis are currently assumed to be uni-
formly distributed over the closed interval [0,D*]. RR is projected to increase linearly from 1 - PRO-
FAC at the dose of D* (> 0+) to a value of 1 as the dose D is reduced to background radiation dose 0+.
For further decreases in dose D below 0+, RR is projected to increase to a value RR* (at absolute zero
radiation) when evaluated relative to the risk at 0+.
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current natural background exposure level, 0+. Figure 3 is used to explain
environmental exposures to low- or high-radiation doses but also can be
used for other forms of exposure (e.g., occupational exposure of nuclear
workers). With the HRR model, low doses and dose rates of radiation
(low-LET component only) are considered to stimulate the above indi-
cated system of protective processes causing RR to decrease progressively
to well below the spontaneous level of 1 (at natural background expo-
sure) for radiation doses somewhat above the natural background radia-
tion dose of 0+ (Figure 3). The total radiation dose D is made up of a low-
LET component DL and high-LET component DH. When the total radia-
tion dose D decreases below the natural background radiation level of 0+,
RR is expected to increase linearly as the low-LET dose component DL
decreases due to a progressive loss of adapted protection. The loss occurs
as DL falls below the individual-specific threshold (stochastic) for activat-
ing the protective processes that contributed to adapted protection (Scott
2006b). Currently, a uniform distribution of these thresholds has been
assumed over the closed dose interval [0,D*], where D* is the minimum
total radiation dose for which the system of protection is activated by the
low-LET component DL* in each irradiated person. 
The dose zone [0,D*] is called Transition Zone A since it contains the
stochastic thresholds for activating the system of protection that con-
tributes to the radiation adaptive response (Scott 2005a, 2006b; Scott et
al. 2006). Above the total dose D*, RR is roughly constant at RR = 1 – PRO-
FAC, over a Zone of Maximal Protection that is relatively wide after low-
rate exposure and narrow after high-rate exposure. Then at higher doses,
protection is lost (PAM process and immune system stimulation) causing
a steep rise in the dose-response curve (Transition Zone B). Just above a
dose where protection is lost in each irradiated person, the curve then
enters the LNT Zone that has been investigated in many epidemiological
studies (NRC 2006) and inappropriately used to justify a LNT extrapola-
tion of cancer risk down to the dose 0+ (the natural background exposure
level). For the LNT Zone, immunity and the PAM process are considered
to be maximally suppressed. Doses in this zone and higher (e.g., doses
associated with conventional fractionated therapy individual dose frac-
tions) may therefore promote metastasis of existing cancer.
For Transition Zone A, changes in RR are determined by DL (Scott
2006b). For the Zone of Maximal Protection, RR is essentially independ-
ent of dose. For Transition Zone B, RR depends both on DL and DH. For
the LNT Zone RR also depends on DL and DH (Scott 2006a,b).
The related cancer RR equation for the HRR model depends on the
radiation exposure scenario. The solution provided below applies for
combined exposures to low- and high-LET radiation for D ≥ 0+. At and
above natural background radiation exposures the cancer RR is charac-
terized by the following equation:
B. R. Scott and J. Di Palma
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RR = 1,
for background radiation exposure (D = 0+), and
RR = (1 – PROFAC)[1 + f(B)(KLDL + KHDH)], (1)
for doses > background.
Here f(B) represents the quotient (1 – B)/B, where B is the baseline
cancer frequency (incidence of mortality depending on the endpoint
modeled). KL and KH are called slope parameters and are associated with
the low- and high-LET components of the radiation, respectively. For
example, with combined exposure to alpha and gamma radiations (as
occurs for radon in the home), KL would be associated with the gamma
rays and KH with alpha radiation. Generally KH > KL (Scott 2006a) in
Equation 1 which was derived from a corresponding equation for neo-
plastic transformation (Scott 2004, 2005a, 2006a) by replacing the spon-
taneous transformation frequency T0 with the baseline cancer frequency
(incidence or mortality) B and using different slope parameters for can-
cer (uppercase “K”) than were used for transformation (lowercase “k”).
Justification for this approach is based on the observation that the RR
dose-response curve for neoplastic transformation and for cancer induc-
tion appear to have the same shape (Redpath et al. 2001; Scott 2005b,
2006a). 
The PROFAC (protection factor) in Equation 1 accounts for radiation
hormesis associated with immune system stimulation and activation of the
PAM process. However, it relates only to the low-LET component of the
dose. When only high-LET alpha radiation is involved, PROFAC is pre-
sumed to be zero (Scott 2006a). For cancer mortality considerations, the
PROFAC represents the expected proportion of deaths avoided as a result
of radiation hormesis among those lives that would otherwise have been
lost to cancer. For cancer incidence considerations, the PROFAC repre-
sents the expected proportion of cancer cases avoided as a result of radia-
tion hormesis among those that would otherwise have occurred. The PRO-
FAC differs for different cancer types and can differ for different exposure
scenarios. For results that are presented later, it has been assumed that
similar PROFACs apply to cancer incidence and cancer mortality. Thus,
PROFACs based both on cancer incidence and cancer mortality have been
used in evaluating expected lives saved due to radiation hormesis.
Regarding Equation 1, for low doses and dose rates (near natural
background levels), the term (1 – PROFAC) is expected to predominate
for exposure only to low-LET radiation as well as for combined exposure
to low- and high-LET radiation. In this case,
RR ≈ 1 – PROFAC. (2)
Sparsely ionizing diagnostic and natural background radiations
239
10
Dose-Response: An International Journal, Vol. 5 [2014], Iss. 3, Art. 8
https://scholarworks.umass.edu/dose_response/vol5/iss3/8
For exposure only to low-LET X-rays or gamma rays, RR = 1 at the nat-
ural background radiation dose and then drops to a value 1 – PROFAC for
doses that active the previously indicated protective processes. Here it is
assumed that the smallest doses of interest above the natural background
radiation dose are sufficient to stimulate the protective processes.
Otherwise, a more complicated approach is needed related to evaluating
stochastic threshold distributions for activating the system of protective
processes (Scott et al. 2004; Scott 2006a). Currently available information
suggests that the protective PAM process may be stimulated by low-LET
radiation doses as low as 0.02 mGy which can be obtained from monthly
background radiation doses in some regions of the globe (Scott, 2005a).
This conclusion is based on a study of radiation-induced inversion muta-
tions in mice (Hooker et al. 2004). For neoplastic transformation, doses
as low as 0.4 mGy have been demonstrated to be protective (Scott 2005a;
Scott et al. 2006). However, there are no data for lower doses except for
exposure of controls to background radiation.
Moderate and high doses can inactivate the PAM process and sup-
press (rather than stimulate) the immune system (Scott 2006a,b;
Hashimoto et al., 1999) leading to increased radiation-associated cancers.
Thus, the increased incidence of cancer at moderate and high doses
relates to the loss of protection against stochastic effects. The RR at mod-
erate and high doses therefore increase as dose increases. The range of
doses over which RR < 1 is expected to increase when the radiation is
given at a low rate and over an extended period (Scott 2004, 2005a,
2006a,b). This is also expected to be the case for exposure to multiple,
small doses, each of which fall in the dose zone where the protective
processes are activated (i.e., hormetic zone). This protective dose zone
depends on the type of radiation and for photons depends on photon
energy (Scott 2005a, 2006a; Scott et al. 2006). For a single dose of diag-
nostic X-rays delivered at a high rate, this protective zone associated with
the PAM process includes doses in the range from 1 mGy to 10 mGy
(Scott, 2005a; Scott et al. 2006). For brief exposures at a high rate to high-
energy gamma rays, doses as high as 100 mGy fall in the hormetic zone
(Scott 2005a; Scott et al. 2006). 
Both RR and standardized mortality ratio (SMR) are used in this
paper to estimate the PROFAC for in vivo considerations where both the
PAM process and immune system stimulation are presumed to contribute
to protection against cancer. The SMR in some cases is used as an estimate
of RR, although these statistics can differ depending on dose lagging and
other assumptions. Odds ratio can also be used as an estimate of RR for
rare diseases.
For exposures at below natural background radiation levels, the RR is
predicted to increase linearly from 1 at current natural background radi-
ation exposure to a value RR* at absolute zero natural background. As
B. R. Scott and J. Di Palma
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dose is increased from the background level to the dose D* in Figure 3,
RR is predicted to decrease from 1 at natural background to 1 – PROFAC.
However, the PROFAC can vary for different individuals, so as used in this
paper PROFAC represents a populations-specific average.
The HRR model is pragmatically applicable to all types of exposures,
be they acute or protracted or fractionated, and is based on high- and
low-LET absorbed radiation doses, rather than on a weighted combina-
tion of these doses.
IMPLICATIONS OF THE DOSE-INDEPENDENT ZONE
With the HRR model, there is a relatively large dose region (Figure 3)
over which RR is suppressed below 1 and relatively independent of dose
(flat portion of curve). This has important implications for ecological
studies of cancer occurrence in elevated radiation environments.
Ecological studies of radiation-induced cancer have been criticized by
advocates of the LNT hypothesis because radiation doses associated with
such studies have large errors, thereby preventing the researchers from
comfortably calculating excess RR per unit dose (a widely used, risk-
assessment tool based on the LNT hypothesis). However, if there is a large
dose region over which RR is independent of dose, then dose errors are
far less important and LNT does not apply!
With the HRR model and for low doses delivered at low rates over
prolonged periods, the dose-independent region of suppressed RR is
expected to include doses to several hundreds of milligray and possibly
much higher. For such a dose-independent region one needs only to esti-
mate the PROFAC in order to fully characterize the radiation response. In
doing so, the expected number of cancer deaths (or cases) avoided (due
to radiation hormesis) per each 100 deaths (or cases) that would other-
wise occur is simply given by 100 × PROFAC, when PROFAC is evaluated
for the type of cancer death (or case) of interest (e.g., lung cancer,
leukemia, etc.). Assuming a binomial distribution for the number of lives
saved (cancer deaths avoided) due to radiation hormesis, the standard
deviation for the expected lives saved is given by the square root of the
variance, where the variance equals 100 × PROFAC(1 – PROFAC). 
DATA SUPPORTING THE HRR MODEL
A similar curve shape as in Figure 3 (HRR model) for doses > D*
where RR is suppressed below 1 at a level of 1 – PROFAC for a wide range
of doses has been observed for lung cancer induction by gamma-ray
exposure of a very large population (> 15,000) of laboratory mice, based
on data from Ullrich et al. (1976). For the indicated data, RR is adequately
described by a curve that decreases from 1 at the background dose 0+ to
a value of 1 – PROFAC at near 100 mGy and remains essentially constant
for doses to 1,000 mGy. The indicated data are presented in Figure 4. The
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241
12
Dose-Response: An International Journal, Vol. 5 [2014], Iss. 3, Art. 8
https://scholarworks.umass.edu/dose_response/vol5/iss3/8
B. R. Scott and J. Di Palma
242
indicated suppression of lung cancer by induced protective processes is
highly significant (p < 6 × 10–8; based on average RR = 0.735 ± 0.05 for the
four nonzero dose groups). The average value for the PROFAC based on
these data is 0.265 ± 0.05. Thus on average, about 27% of the sponta-
neous lung cancers were prevented by radiation hormesis for doses over
the range 100 to 1,000 mGy. The central solid line in Figure 4 is just the
average of the four RR values plotted at doses > 0 and corresponds to 1 –
PROFAC. The dashed curves are approximate 95% confidence intervals
assuming a dose-independent normal distribution for RR for doses in the
range 100 to 1,000 mGy. The data are consistent with the existence of a
large dose-independent zone (correlation coefficient R 2 = 0.03 for RR vs.
dose for doses ≥ 100 mGy). There is no evidence for doses < 1,000 mGy
being associated with an increase in cancer risk as would be predicted
using the LNT hypothesis! In a later paper the researchers (Ullrich and
Storer 1979) indicated having detected a systematic error related to lung
tumor detection. However, correcting such a systematic error would not
be expected to alter the RR curve shape presented here.
The dose-response curve shape in Figure 4 has also been demon-
strated for lung cancer induction in humans exposed to fractionated low-
LET radiation for absorbed doses up to about 1,000 mGy of diagnostic X-
rays as shown in Figure 5 (Canadian Fluoroscopy Cohort Study, Howe
1995). Data points are presented separately for males and females.
Published dose bins (Howe 1995) were used with the data points plotted
at the midrange of the bins. The low-LET data used were based on mul-
tiple applications of diagnostic X-rays given to TB patients. The data in
Figure 5 are consistent with the notion that fractionated exposures to
diagnostic X-rays over and over stimulate the removal of precancerous
neoplastically transformed cells from the lung and thereby reduce the
risk of lung cancer (medical radiation hormesis). There is no evidence
FIGURE 4. Lung cancer RR based on more than 15,000 mice exposed at Oak Ridge National
Laboratory to gamma rays based on data reported by Ullrich et al. (1976). The notation 0+ is used to
indicate the natural background radiation dose, presented as though it were located at zero.
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that fractionated diagnostic X-ray doses ≤ 1,000 mGy are causing excess
lung cancers as would be predicted based on the LNT hypothesis!
Instead, there is strong evidence for medical radiation hormesis.
A similar curve shape has also been used (Scott 2004) to characterize
lung cancer risk in Mayak plutonium facility workers chronically exposed
at low rates over years to gamma radiations based on data reported by
Khokhryakov et al. (1996). The results presented here were corrected for
exposure to alpha radiation (Scott 2006a) using the HRR model. The
dose-response curve and 95% confidence region is presented in Figure 6
and shows the high degree of protection that appears to be associated
with exposure over years at low rates to gamma rays. The average value for
PROFAC was 0.86 ± 0.07 (Scott, 2004), similar to the very large but con-
troversial PROFAC (> 0.95) reported for chronic gamma-irradiation-
induced protection against cancer in Taiwanese citizens (Chen et al.
2004) residing in apartments built of steel contaminated with cobalt-60 (a
gamma-ray source). The gamma-ray dose appears not only to have pro-
tected against cigarette-smoking-associated lung cancers in the Mayak
workers, but also against alpha-radiation-induced lung cancer (Scott
2006a). Russian national statistics were used to obtain risk estimates for
an unexposed population. The results in Figure 6 are consistent with the
view that chronic exposure of humans at a very low rate over years to
gamma radiation over and over activate the system of transient protective
processes that contribute to radiation adaptive response (hormesis).
Small X-ray doses have been demonstrated to suppress lung metasta-
sis of squamous carcinoma cells transplanted into mice (Sakamoto 2004).
The dose-response curve shapes for suppressing lung metastasis in vivo
FIGURE 5. Applications of the HRR model to lung cancer data for humans (TB patients) exposed
to fractionated X-ray (diagnostic) doses, based on data reported by Howe (1995). Data for males and
females were jointly analyzed. The two dashed curves indicate the 95% confidence region RR = 1 -
PROFAC. The central curve is based on the average value for RR for the four data points. Such aver-
aging is justified based on the HRR model. The notation 0+ is used to indicate the natural back-
ground radiation dose, presented as though it were located at zero.
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and for suppressing neoplastic transformation in vitro by low doses of X-
rays (or gamma rays) are quite similar. The indicated curves have shapes
similar to that for RR in Figure 3 for doses ≥ 0+. Low doses caused a reduc-
tion both in transformation frequency and lung metastasis below the
value for controls not receiving any radiation exposure. The PAM process
and induced high-fidelity DNA repair are thought to be responsible for
the in vitro suppression of neoplastic transformation (Scott 2004).
However for transplanted squamous carcinoma cells, induced DNA
repair could not explain suppression of lung metastasis. More likely con-
tributors to the in vivo suppression of metastasis are activation of the PAM
process and enhanced immunity. Moderate and high doses, however,
inhibit the PAM process and suppress immunity so that the dose-response
curve for lung metastasis would be expected to rise to above the value for
controls, as was observed by Sakamoto (2004).
ADDITIONAL EVIDENCE THAT RADIATION EXPOSURE OF HUMANS IS
PREVENTING CANCER 
Values of PROFAC significantly > 0 for cancer occurrence (or cancer
mortality) demonstrate a suppression of cancer (i.e., cancer prevention).
Estimates of PROFAC for a number of irradiated populations (popula-
tions exposed to elevated background radiation and nuclear workers)
have been derived based on cancer mortality data reported by Jaworowski
(2001) and are presented in Table 3 along with estimates based on addi-
tional data. Radiation exposures were presumed to have occurred in the
hormetic zone in cases where RR or the SMR was < 1. All indicated PRO-
FIGURE 6. Applications of the HRR model to lung cancer mortality data for Mayak workers chroni-
cally exposedover years to gamma and alpha radiation at low rates. Results presented were adjusted
for the influence of alpha irradiation (Scott 2006a). Only the gamma-ray dose (for an arbitrary dose
range) is therefore indicated. The notation 0+ is used to indicate the natural background radiation
dose, presented as though it were located at zero.
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FAC values were significantly > 0 (p < 0.05). Results for seven populations
all exposed to low- or low- plus high-LET radiation at low rates or to frac-
tionated diagnostic X-rays are presented in Table 3. PROFAC values range
from 0.15 (15% of spontaneous cancers prevented) for Chernobyl acci-
dent recovery workers to 0.86 (86% of spontaneous cancers prevented)
for Mayak workers. Even residing in U.S. states with high natural back-
ground appears to suppress cancer occurrence (PROFAC = 0.15). 
As previously indicated, the product 100 × PROFAC gives the expect-
ed number of deaths from cancer avoided due to radiation-induced adap-
tive protection (hormesis) for each 100 cases that would have otherwise
occurred. Thus, for Mayak workers, 86 lung cancer deaths are expected
to have been prevented for each 100 lung cancer deaths that would have
otherwise occurred in the absence of their chronic exposure to gamma
radiation. This is a pronounced level of protection against normally
occurring harm, including harm associated with cigarette smoking.
EXPECTED IMPACT OF AGE AT EXPOSURE ON THE PROFAC
DNA repair fidelity is known to be reduced with increasing age
(Szczesny et al. 2003). Thus, genomic instability is expected to increase as
we age because of reduced DNA fidelity. However, increasing genomic
instability would be expected to be associated with an increased role of
the PAM process and immune system stimulation in protecting against
genomic-instability-associated diseases such as cancer. The PAM process
involves signaling between normal and aberrant cells. The higher the
concentration of genomically unstable cells the stronger the signaling
TABLE 3. Central estimates of the radiation-hormesis-related protection factor (PROFAC) against
cancer in humans
Group Effect Radiation types PROFAC
Chernobyl accident recovery workers Cancers Low- plus high-LET 0.13a
(Ivanov et al., 2001)
USA, residents of high background states Cancers Low- plus high-LET 0.15a
(Frigèrio and Stowe, 1976)
British medical radiologistsb after Cancers Low-LET 0.29a
1955-1979 (Berrington et al., 2001)
High residential radon, USA (Cohen, 1995) Cancers Low- plus high-LET 0.35a
Canadian nuclear industry workers Leukemia Low- plus high-LET 0.68a
(Gribbin et al., 1992)
USA DOE facilities workers Leukemia Low- plus high-LET 0.76a
(Gilbert et al., 1993)
Russian Mayak plutonium facility Lung cancer Low- plus high-LET 0.86a,c
workers (Scott, 2006a)
aPROFAC significantly > 0 (p < 0.05).
bEvaluated relative to all men in England and Wales.
cBayesian posterior mean with an associated standard deviation of 0.07.
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associated with the PAM process is expected to be, once signaling is initi-
ated (Scott 2004). Thus, one would expect the PROFAC to increase as age
increases for a given genomic-instability-associated disease. This appears
to be the case based on PROFAC estimates presented in Figure 7 for radi-
ation-induced protection against breast cancer after multiple mammo-
grams (related to diagnostics for breast cancer occurrence). The data are
based on Nyström et al. (2002). The results appear to indicate that the
aged benefit more from induction of the PAM process and immunity
than young adults. Whether or not the very young will benefit from the
PAM process is unclear. Induced immunity would be expected to prove
beneficial even for the very young.
THERAPEUTIC RADIATION HORMESIS IMPLICATIONS
The relatively large PROFAC values in Figure 7 are consistent with the
view that the transient protective processes (PAM process and induced
immunity) can be activated over and over via fractionated exposures to
low doses in the hormetic zone. Such repeated doses would also be
expected to remove a fraction of the existing cancer cells (therapeutic
radiation hormesis at low doses). However, cancer cells are known to
resist undergoing apoptosis (PAM process resistance) (Scott, 2004).
Ongoing cancer therapy and cancer prevention research is leading to
new discoveries of agents that sensitize cancer cells to undergo apoptosis.
One such agent is the natural phenolic compound resveratrol (3,4′,5,-tri-
hydroxystilbene) which is present in significant amounts in red wine,
grapes, peanuts, green vegetables, in other edible spermatophytes, and in
many oriental herbal beverages (e.g., green tea) and medicines (Fiore et
al., 2005; Sgambato et al. 2000). 
FIGURE 7. Proportion of breast cancer prevented (PROFAC) due to radiation hormesis as a function
of age at exposure to diagnostic X-rays. Based on data for fractionated exposure (mammograms) of
humans during breast cancer screening (Nyström et al. 2002).
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Resveratrol has been shown to potentiate the apoptotic effects of
gamma radiation, cytokines (e.g., TRAIL), and chemotherapeutic agents
(Aggarwal et al. 2004). In addition to beneficial cardiovascular effects,
resveratrol exhibits anticancer properties, as suggested by its ability to
suppress proliferation of a wide variety of tumor cells, including myeloid
and lymphoid cancers; multiple myeloma; cancers of the stomach,
prostate, breast, colon, thyroid and pancreas; melanoma; squamous cell
cancinoma in the head and neck; ovarian carcinoma; and cervical carci-
noma (Aggarwal et al. 2004).
The cancer suppressive effects of resveratrol involve signaling
through multiple pathways (e.g., to apoptosis) and are mediated via the
following (Aggarwal et al. 2004): (1) cell cycle arrest; (2) upregulation of
p21Cip1/WAF1, p53, and Bax; (3) downregulation of survivin, cyclin D1,
cyclin E, Bcl-2, Bcl-xL and cIAPs; and (4) activation of caspases. Resveratrol
has been demonstrated to suppress the activation of transcription factors
that include AP-1, NF-κB, and Egr-1; to inhibit protein kinases including
IkBα kinase, JNK, MAPK, Akt, PKD, PKC, and casein kinase II; and to
down-regulate products of genes that include IL-1, IL-6, IL-8, AR, COX-2,
5-LOX, VEGF, and PSA.
The ability of resveratrol to trigger apoptosis (likely the PAM process)
has been established in different human tumor cell lines (Hsieh and Wu
1999; Clement et al. 1998; Surh et al. 1999; Ahmad et al. 2001; Dorrie et al.
2001; Tinhofer et al. 2001). Joint applications of fractionated or protract-
ed low-dose irradiation (low-LET) in combination with applications of
resveratrol may lead to enhanced selective killing of cancer cells (genom-
ically unstable cells selectively removed via the PAM process). Such low-
dose combined therapy would likely be preferred by cancer patients over
current high-dose radiation and chemotherapy which are associated with
severe side effects. However, new research is needed to develop optimal
dosing schemes. Common low-LET radiation sources used in medical
diagnostics could be used in this form of combined therapy, including
those used in nuclear medicine. Further, low-dose/dose-rate radioim-
munotherapy could be employed in combination with applications of
apoptosis-sensitizing agents (for selectively sensitizing cancer cells), such
as resveratrol, in curing cancer while minimizing side effects. Other plant
polyphenols that also sensitize cancer cells to undergoing apoptosis are
genistein, curcumin, emodin, and flavopiridol (Garg et al. 2005). Multiple
pathways to apoptosis may be associated with the indicated sensitizers
since multiple pathways are known to be associated with resveratrol-
induced apoptosis (Aggarwal et al. 2004). These pathways include the Fas
pathway, mitochondrial pathway, Rb-E2F/DP pathway, p53-activation
pathway, the ceramide-activation pathway, the tubulin-polymerization
pathway, and the Adenyl-cyclase pathway.
Sparsely ionizing diagnostic and natural background radiations
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Low-dose radiation therapy (i.e., therapeutic radiation hormesis) has
already been reported to be successful for some types of cancer (Chaffey
et al. 1976; Choi et al. 1979; Sakamota et al. 1997; Richaud et al. 1998;
Cuttler et al. 2000; Cuttler and Pollycove 2003; Sakamota 2004; Kaminski
et al. 2005). Fractionated, low-dose, total-body, and half-body external
beam therapy has been used successfully by several medical groups in
treating non-Hodgkin’s lymphoma (Chaffey et al. 1976; Choi et al. 1979;
Richaud et al. 1998; Cuttler et al. 2000, Cuttler and Pollycove 2003;
Sakamota 2004). Small individual doses (called fractions) are adminis-
tered after designated time intervals over a given time period. Dose frac-
tion sizes used in treating non-Hodgkin’s lymphoma have been relatively
large, e.g., 100 to 150 mGy (Cuttler et al. 2000). Our research results indi-
cate that much smaller fraction sizes may be equally effective and, if so,
would allow for considerable extension of the total period over which
dose fractions were given.
Therapeutic radiation hormesis has also been successfully employed
to treat ovarian, colon, and hematologic cancer, with no symptomatic side
effects (Cuttler and Pollycove 2003; Sakamoto 2004). Low-dose, low-dose-
rate radioimmunotherapy (a form of radiation hormesis involving beta
radiation) has also been used successfully in treating follicular lymphoma
(Kaminski et al. 2005). 
The PAM process is expected to be more efficiently activated by low-
dose-rate and fractionated exposures than by high-dose-rate and single
exposures. The time interval between the dose fractions could be quite
critical. For new research, biweekly or once monthly fractions could be ini-
tially investigated. The number of fractions could be large without serious
side effects, so long as small fraction sizes (e.g., 0.5 to 1 mGy) were used.
ENVIRONMENTAL RADIATION HORMESIS 
Numerous studies have demonstrated that environmental exposures
to ionizing radiation can suppress cancer and other diseases (environ-
mental radiation hormesis). Indeed, immune responses have been found
to be upregulated among inhabitants of high natural background radia-
tion areas (Luckey 1991; Safwat 2000; Kojima et al. 2002). Table 4 shows
PROFAC estimates for environmental radiation hormesis associated with
exposure to elevated levels of radon. The PROFAC estimates are based on
SMR values reported by Mifune et al. (1992) based on a study of cancer
deaths (1952 – 1991) for persons residing in a high-level radon spa area
of Japan. The SMR was evaluated relative to the Japanese population. The
results in Table 4 suggest that many lives are being saved worldwide due
to environmental radiation hormesis (e.g., associated with radon expo-
sure in the home). The results also support the use of radon in the treat-
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ment and prevention of genomic-instability-associated diseases. Immune
system stimulation from radon exposure may also be protecting us from
diseases not associated with genomic instability. Eliminating radon from
the home (often costly for homeowners) therefore may be causing an
increased risk of diseases. 
With our HRR model, one can calculate the expected impact of
reducing natural background ionizing radiation to zero. For such calcu-
lations, it is convenient to use normalized dose DL/b where b is any refer-
ence background low-LET radiation dose over the period of interest. Our
previous research has revealed that only DL (the low-LET dose) is impor-
tant for evaluating cancer risk at below natural background radiation
exposures (Scott 2006b). This is because thresholds for activating adapt-
ed protection depend on DL but not on DH. Changes in risk at below nat-
ural radiation levels is modeled via the HRR model as being related to
loss of adapted protection. Each individual has a different threshold dose
(stochastic) DL for activating the system of protective processes discussed.
Assuming the indicated stochastic thresholds to be uniformly distributed
over the interval 0 (absolute zero natural background radiation) to the
dose D* (which exceeds background radiation dose 0+) in Figure 3, the
RR can be characterized by the following linear relationship:
RR = S + (1 – S)RR* (3)
where RR* is the relative risk at absolute zero natural ionizing radiation
dose and S = DL/b is the normalized dose relative to an arbitrarily
assigned reference background radiation dose b. RR takes on a value of 1
at S = 1, which correspond to the absorbed dose DL = b. Figure 8 shows
results of applying Equation 3 to environmental radiation hormesis data
for solid cancer mortality in Yangjiang, China based on data for the years
1979 – 1998 reported by Wei and Sugahara (2002). Normalized doses
were evaluated relative to a cumulative dose of 450 mSv. Here it was
TABLE 4. Central estimates of high-level, radon-associated PROFACs against cancer at different sites
in the body based on cancer mortality data for persons residing in a high-level radon spa area in
Japan (Mifune et al. 1992)
PROFACa






aPresumed to be associated with environmental radiation hormesis.
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assumed that the low-LET component of the dose was proportional to the
total dose in millisieverts. Thus, the normalized dose based on millisiev-
erts estimates the normalized dose based on DL. Three curves are pre-
sented in Figure 8: central, lower, and upper bounds. The central curve
is based on constrained linear regression. Straight lines were drawn from
each data point through the coordinates (RR = 1, S = 1). The average of
these lines was used for the central curve. The upper and lower bound
curves are subjective and are based on the curves with the steepest and
shallowest slopes. RR is projected to increase between 1.3- and 2.0-fold as
background radiation is reduced to absolute zero.
Similar results are shown in Figure 9 for cancer among inhabitants of
various cites and states in India, based on data from an ecological study
conducted by Nambi and Soman (1987). Normalized dose was evaluated
relative to an annual gamma-ray dose of 850 μGy (a relatively large dose)
from natural background radiation. Thus, only gamma-ray doses were
used. Cancer RR is projected to increase 2.0- to 2.8-fold as natural back-
ground radiation is reduced to absolute zero.
For calculations associated with Figures 8 and 9, it was assumed that
high-fidelity DNA repair is not lost at near absolute zero background radi-
ation, which may not be the case. In vivo mutation data of Hooker et al.
(2004) that we have previously modeled indicated the loss of high-fideli-
ty DNA repair after ultra low X-ray doses (Scott, 2005a; Scott et al. 2006)
when cells from irradiated mice were frozen shortly (3 hours) after irra-
diation (not allowing for background radiation to build to a level which
would trigger protective processes). Mutation risk increases by orders of
FIGURE 8. Expected effects of reducing natural background radiation on cancer mortality, based on
solid cancer mortality data for Yangjiang, China, reported by Wei and Sugahara (2002). Central
(from constrained linear regression), and subjective upper and lower bound curves are presented.
Normalized doses S were evaluated relative to a total dose of 450 mSv.
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magnitude apparently due to the loss of high-fidelity DNA repair along
with loss of the PAM process. Thus, the increases indicated in Figures 8
and 9 as S approaches 0 (absolute zero ionizing radiation dose) may be
greatly underestimated. Background low-LET ionizing radiation may be
essential for making high-fidelity DNA repair available on a regular basis
to all mammalian life. The possibility that high-fidelity DNA repair may
be significantly less available after low radiation doses has been proposed
by others based on experimental measurements of DNA double-strand
break repair using a sensitive assay (Rothkamm and Löbrich 2003).
Further, in vitro data for gamma-ray induced chromosomal aberrations in
human lymphocytes suggest differing fidelity for DNA repair after low
and moderate doses delivered at low or high rates (Zaichkina et al. 2004).
Low-fidelity repair was implicated for doses < 200 mGy and a much high-
er fidelity repair for doses between 200 and 500 mGy.
CONCLUSIONS
• Environmental radiation hormesis associated with radon in our homes
and with elevated background radiation (low- or low- plus high-LET)
appears to be preventing many cancer deaths.
• Medical radiation hormesis associated with routine applications of
diagnostic chest X-rays, mammograms, and CT scans may be prevent-
ing cancer occurrence through stimulating the removal of precancer-
ous neoplastically transformed cells. Medical and environmental radia-
tion hormesis may also be preventing metastasis of existing cancer.
FIGURE 9. Expected effects of reducing natural background radiation on cancer relative risk based
on data for various cities and states of India reported by Nambi and Soman (1987). Central (from
constrained linear regression), and subjective upper and lower bound curves are presented.
Normalized doses S were evaluated relative to an annual gamma-ray dose of 850 μSv.
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• Low-dose therapeutic radiation hormesis associated with fractionated
exposure to small X-ray doses has been used to successfully treat non-
Hodgkin’s lymphoma and ovarian, colon, and hematologic cancer.
• Low-dose, low-dose-rate therapeutic radiation hormesis associated with
application of radiolabeled antibodies (beta radiation source) has been
used successfully to treat follicular lymphoma.
• Low-dose therapeutic radiation hormesis in combination with apopto-
sis-sensitizing agents such as resveratrol could be used to successfully
cure cancer. 
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